Patrick Cobb - Concepedia

Author

Patrick Cobb

Also Known As

Ardaman Shergill, M. Cairo, P Cobb, P W Cobb, P. Cobb, P. W. Cobb, P.W. Cobb, PATRICK W. COBB, Patrick Cobb, Patrick W Cobb

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

Dana-Farber Cancer Institute St. Vincent's HealthCare West Cancer Center Texas Oncology Queen Mary University of London

About

Patrick Cobb is an author at Dana-Farber Cancer Institute specializing in oncology, radiation oncology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	811
2	Public Health	2	2	23
3	Health Sciences	1	1	49
4	Biostatistics	1	1	12
5	Immunology	1	1	19

Patrick Cobb

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, The Lancet Oncology First-line TherapyUrologyChemotherapy Versus ChemotherapyGenitourinary CancerMedicine	2021	627
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Thomas Powles, Piotr Tomczak, Se Hoon Park, The Lancet Oncology	2022	262
Symptom trajectories during chemotherapy in outpatients with lung cancer colorectal cancer, or lymphoma Jeannine M. Brant, Susan L. Beck, William N. Dudley, European Journal of Oncology Nursing OncologyCancer ManagementColorectal CancerSymptom TrajectoriesMedicine	2011	49
Symptom Trajectories in Posttreatment Cancer Survivors Jeannine M. Brant, Susan L. Beck, William N. Dudley, Cancer Nursing	2010	47
Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion Howard A. Burris, Ahmad Awada, John G. Kuhn, Anti-Cancer Drugs	1994	44
Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial Carlo Palmieri, Hannah M. Linden, Stephen N. Birrell, The Lancet Oncology	2024	42
A Phase II Trial of DaunoXome, Liposome- Encapsulated Daunorubicin, in Patients with Metastatic Adenocarcinoma of the Colon John R. Eckardt, Elizabeth Campbell, H. A. Bums, American Journal of Clinical Oncology	1994	37
Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, correlates with the degree of AR positivity in advanced AR+/estrogen receptor (ER)+ breast cancer in an international phase 2 clinical study. Carlo Palmieri, Hannah M. Linden, Stephen N. Birrell, Journal of Clinical Oncology Breast OncologyAr PositivityAr ExpressionPathologyPharmacotherapy	2021	34
Eflapegrastim, a Long-Acting Granulocyte-Colony Stimulating Factor for the Management of Chemotherapy-Induced Neutropenia: Results of a Phase III Trial Lee S. Schwartzberg, Gajanan Bhat, Julio A. Peguero, The Oncologist	2020	28
Isolation of primitive hematopoietic stem cells. Patrick Cobb, C. Frederick LeMaistre PubMed	1992	23

Page 1